

DAFTAR PUSTAKA

1. Birlea SA, Spritz RA, Norris DA. Vitiligo. Dalam: Wolff K, Goldsmith LA, Katz SI, Gilchrist BA, Paller AS, Leffel DJ, penyunting. Fitzpatrick's dermatology in general medicine. Edisi 8, Volume 1. New York: McGraw Hill companies. 2012: 792-803.
2. Taieb A, Picardo M. Epidemiology, definitions and classification. Dalam: Picardo M, Taieb A, penyunting. Vitiligo. Roma: Springer. 2008: 13-24.
3. Feily A. Vitiligo Extent Tensity Index (VETI) score: a new definition, assesment and treatment evaluation criteria in vitiligo. *Dermatology Practical and Conceptual*. 2014; 4(4): 81-4.
4. Gawkrödger DJ, Ormerod AD, Shaw L, Mauri-Sole I, Whitton ME, Watts MJ, dkk. Guidline for the diagnosis and management of vitiligo. *British Journal of Dermatology*. 2008; 159: 1051-76.
5. Bilal A, Anwar I. Guidelines for the management of vitiligo. *Journal of Pakistan Association of Dermatologists*. 2014; 24(1): 68-78.
6. Parsad D. Natural history and prognosis. Dalam: Picardo M, Taieb A, penyunting. Vitiligo. Roma: Springer. 2008: 139-42.
7. Aghei S, Sodaifi M, Jafari P, Jafari P, Mazharinia N, Finlay AY. DLQI Scores in vitiligo: reliability and validity of the Persian version. *Boston Medical Center Dermatology*. 2004; 4(8): 1-8.
8. Lotti T, D'Erme AM. Vitiligo as a systemic disease. *Clinics in Dermatology*. 2014; 32: 430-4.
9. Choi D, Isedeh P, Hamzavi IH. Vitiligo: a review of the pathogenesis. *Journal of the Egyptian Women's Dermatologic Society*. 2014; 11: 145-58.
10. Koshoffer A, Boissy RE. Current understanding of the etiology of vitiligo. *Current Dermatology Reports*. 2014; 3: 1-5.
11. Gude D. Vitiligo: Newer insight in pathophysiology and treatment. *Indian Journal of Paediatric Dermatology*. 2012; 13: 27-33.
12. Picardo M, Taieb A. Pathophysiologi overview. Dalam: Picardo M, Taieb A, penyunting. Vitiligo. Roma: Springer. 2008: 149-152.
13. Glassman SJ. Reactive oxygen species and vitiligo. Dalam: Laher I, penyunting. *System biology of free radicals and antioxidants*. Berlin: Springer. 2014: 3677-94.

14. Picardo M, Dell 'Anna ML. Oxidative stress. Dalam: Picardo M, Taieb A, penyunting. Vitiligo. Roma: Springer. 2008: 231-8.
15. Manga P, Orlow SJ. Engineering a new mouse model for vitiligo. *The Journal of Investigative Dermatology*. 2012; 132: 1752-5
16. Glassman SJ. Vitiligo, reactive oxygen species and T-cells. *Clinical Science*. 2011; 120: 99-120.
17. Ueland PM, Refsum H, Stabler SP, Malinow MR, Anderson A, Allen RH. Total homocysteine in plasma or serum methods and clinical application. *Clinical Chemistry*. 1993; 39(9): 1764-78.
18. Mayer EL, Jacobsen DW, Robinson K. Homocysteine and coronary atherosclerosis. *Journal of the American College of Cardiology*. 1996; 27 (3): 517-27
19. Shaker OG, El-Tahlawi SMR. Is there a relationship between homocysteine and vitiligo? A pilot study. *British Journal of Dermatology*. 2008; 159: 720-4.
20. Sabry HH, Sabry JH, Hashim HM. Serum level of homocysteine, vitamin B12 and folic acid in vitiligo. *Egyptian Journal of Dermatology and Venereology*. 2014; 34: 65-9.
21. Ghalamkarpour F, Jafarian Z, Einollahi H, Younespour S. Serum homocysteine: is it a biomarker for vitiligo?. *Pigmentary Disorders*. 2015; 2(4): 1-4.
22. Silverberg J, Silverberg N. Serum homocysteine as a biomarker of vitiligo vulgaris: a pilot study. *Journal of the American Academy of Dermatology*. 2010; 64:445-7.
23. Karadag AS, Tural E, Ertugrul DT, Akin KO, Bilgili SG. Serum holotranscobalamine, vitamin B12, folic acid and homocysteine levels in patient with vitiligo. *Clinical and Experimental Dermatology*. 2011; 37: 62-4.
24. El-Dawela RE, Abou-elfetouh S. Relationship between homocysteine, vitamin B12, folic acid levels and vitiligo. *Journal of Applied Sciences Research*. 2012; 8(11): 5528-35.
25. Singh S, Usha S, Pandey SS. Increased level of serum homocysteine in vitiligo. *Journal of Clinical Laboratory Analysis*. 2011; 25: 110-2.
26. Yasar A, Gunduz K, Onur E, Calkan M. Serum homocysteine, vitamin B12, Folic acid levels and methylenetetrahydrofolate reductase (MTHFR) gene polymorphism in vitiligo. *Disease Markers*. 2012; 33: 85-9.

27. Alghamdi KM, Kumar A, Taieb A, Ezzedin K. Assessment methods for the evaluation of vitiligo. *Journal of the European Academy of Dermatology and Venereology*. 2012; 26(12): 1463-71.
28. Zaki Am, Abdo HM, Ibrahim IM, Ibrahim AEK. Serum homocysteine and vitiligo. *The Gulf Journal of Dermatology and Venereology*. 2014; 21(2): 15-20.
29. Gauthier Y, Benzekri L. Non-cultured epidermal suspension in vitiligo: from laboratory to clinic. *Indian Journal of Dermatology Venereology and Leprology*. 2012; 78(1): 59-63.
30. Pusparini AA, Bramono K, Soebaryo RW, Soewoto H. Perbandingan aktivitas enzim siperoksid dismutase dan kadar malondialdehid pada vitiligo generalisata. *Media Dermato-venereologica Indonesiana*. 2009; 36(2): 60-5.
31. Rizal Y, Lestari K. Insiden vitiligo di Poliklinik kulit dan kelamin RSUP Dr. M. Djamil Padang tahun 2001-2006. 2nd Conference of the Asian Society Pigmentary Cell Reseach. Singapore 2007.
32. Putri EK, Yenny SW, Lestari S. Karakteristik pasien vitiligo di Poliklinik Imu Kesehatan Kulit dan Kelamin RS dr. M. Djamil Padang periode Januari 2010 - Desember 2013. *Kongres Nasional Perdoski*; 2014; Bandung.
33. Nascimento LM, Castro CC, Tarle RG, Mira MT. Vitiligo-Part 1. *Anais Brasileiros de Dermatologia*. 2014; 89(3): 461-70.
34. Laddha NC, Dwivedi M, Mansuri MS, Gani AR, Ansarullah M, Ramachandran AV, dkk. Vitiligo: interplay between oxidative stress and immune system. *Experimental Dermatology*. 2013; 22: 245-250.
35. Manga P, Orlow SJ. Engineering a new mouse model for vitiligo. *The Journal of Investigative Dermatology*. 2012; 132: 1752-5
36. Kamel N, Sobhy N, Kamal H, Ismail M. A comparative study of oxidant-antioxidant status in blood and tissue in vitiligo patients. *Egyptian Dermatology Journal*. 2010; 6: 1-10.
37. Qiu L, Song Z, Setaluri V. Oxidative stress and vitiligo: the Nrf2-ARE signaling connection. *Journal of Investigative Dermatology*. 2014; 134: 2074-5
38. Zhe J, Pu S. Impaired activation of Nrf2-ARE signaling pathway undermines H₂O₂-induced oxidative stress response: a possible mechanism for melanocyte degeneration in vitiligo. *Journal of Investigative Dermatology*. 2014; 134: 2221-30.

39. Schallreuter, KU, Rubsam K, Gibbons, NCJ, Maitland DJ, Chavan B, Zothner C, dkk. Methionine sulfoxide reductase A and B are deactivated by hydrogen peroxide (H₂O₂) in the epidermis of patients with vitiligo. *Journal of Investigative Dermatology*. 2008; 128: 808-15.
40. Dell 'Anna ML, Maresca V, Briganti S, Camera E, Falchi M, Picardo M. Mitochondrial impairment in peripheral blood mononuclear cells during the active phase of vitiligo. *Journal of Investigative Dermatology*. 2001; 117: 908-13
41. Dell 'Anna, Urbanelli S, Mastrofrancesco A, Camera E, Iacovelli P, Leone G, dkk. Alterations of mitochondria in peripheral blood mononuclear cells of vitiligo patients. *Pigment Cells Research*. 2003; 16: 553-9.
42. Kawakami T, Hashimoto T. Disease severity indexes and treatment evaluation criteria in vitiligo. *Dermatology Research and Practice*. 2011; 10: 1-3.
43. Hamzavi I, Jain H, McLean D, Shapiro J, Zeng H, Lui H. Parametric modeling of Narrowband UV-B phototherapy for vitiligo using a novel quantitative tool, the vitiligo area scoring index. *Archives of Dermatology*. 2004; 140: 677- 83.
44. Finkelstein JD, Martin JJ. Homocysteine. *The International Journal of Biochemistry and Cell Biology*. 2000; 32: 385-9.
45. Guillams TG. Homocysteine: a risk factor worth treating. *The Standard*. 2004; 6(1): 1-7.
46. House JD, Jacobs RL, Stead LM, Brosnan ME, Brosnan JT. Regulation of homocysteine metabolism. *Advance Enzyme Regular*. 1999; 39: 69-91.
47. Denat L, Kadekaro AL, Marrot L, Leachman SA, Abdel-Malek, ZA. Melanocytes as instigator and victims of oxidative stress. *Journal of Investigative Dermatology*. 2014; 134: 1512-8.
48. Kutlubay Z, Uzuncakmak TK, Engin B, Tuzun Y. Vitiligo and oxidative stress. *Journal of the Turkish Academy of Dermatology*. 2011; 5(4): 1-4
49. Wijaya W. Hubungan kadar homosistein serum dengan abortus spontan (Tesis). Makasar: Fakultas Kedokteran Universita Hasanudin; 2011.
50. Jenkins NC, Grossman D. Role of melanin in melanocyte dysregulation of reactive oxygen species. *BioMed Research International*. 2013; 9: 1-3.
51. D'Angelo A, Selhub J. Homocysteine and trombotic disease. *Blood*. 1997; 98(1): 1-11.

52. Welch GN, Loscado JL. Homocysteine and atherotrombosis. *The New England Journal of Medicine*. 1998; 33: 8-15
53. Jacobsen DW. Hyperhomocysteinemia and oxidative stress. *Arteriosclerosis Thrombosis and Vascular Biology Journal Impact*. 2000; 20: 1182-4.
54. Bickers D, Athar M. Oxidative stress in the pathogenesis of skin disease. *Journal of Investigative Dermatology*. 2006; 126: 2565-75.
55. Pastore S, Korkina L. Redox imbalance in T cell-mediated skin diseases. *Mediator of inflammation*. 2010; 10: 1-9.
56. Getotek A, Skrzydlewska E. The role of transcription factor Nrf2 in skin cells metabolism. *Archives of Dermatological Research*. 2015; 307: 385-96.
57. Reish O, Townsend D, Berry SA, Tsai MY, King RA. Tyrosinase inhibition due to interaction homocysteine with cooper: The mechansims for reversible hypopigmentation in homocysteinuriadue to cystathionine beta-synthase deficiency. *American Journal Human Genetics*. 1995; 57: 127-32.
58. Dahlan S. Langkah-langkah membuat proposal penelitian bidang kedokteran dan kesehatan. Edisi ke-2. Jakarta: Sagung Seto; 2012.
59. Agarwal S, Mendiratta V, Chander R, J Anju, Yadav P. Study of serum level of vitamin B12, folic acid and homocysteine in vitiligo. *Pigment International*. 2015; 2(2): 76-80.
60. Hasanah D, Cipto H, Zubier F, Jacoeb TNA. Korelasi kadar homosistein serum dengan derajat keparahan psoriasis vulgaris. *Media Dermato-venereologica Indonesiana*. 2013; 40: 2-8.
61. Hamza AM, Farid CI, El-sayed ET, Kadeeb HAR. Assessment of serum homocystein level in patients with nonsegmental vitiligo. *Egyptian Journal of Dermatology and Venereology*. 2015; 35: 59-64.